ADCT - LOTIS-7 Phase 1b Trial Data Update
Jun 30, 2025, 12:00:00 AM UTC
Summary
Initial data from the LOTIS-7 trial of ZYNLONTA plus glofitamab showed a 94% best ORR and 72% CR rate, with a data update expected in Q2 2025.
Company
ADC THERAPEUTICS SA (ADCT)NYSE — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.adctherapeutics.comSimilar Events
LOTIS-5 Phase 3 Trial Data Update
Enrollment in the LOTIS-5 Phase 3 trial of ZYNLONTA plus rituximab is complete, with a data update anticipated in late 2025 after PFS events.
clinical readoutLOTIS-7 Data Presentation at EHA2025
ADC Therapeutics will present updated data from the LOTIS-7 trial during a poster session on June 14, 2025, at the EHA2025 Congress in Milan, Italy. The trial evaluates the efficacy of ZYNLONTA in combination with glofitamab for patients with relapsed/refractory DLBCL, showing promising results with an overall response rate of 95.5%.
clinical readoutLOTIS-5 Trial Topline Results
ADC Therapeutics anticipates sharing topline results of the LOTIS-5 trial's primary endpoint analysis by the end of 2025, which may support a supplemental BLA submission in Q1 2026.
clinical readoutClinical Development Updates for LOQTORZI and Pipeline Candidates
Coherus plans to advance its novel immuno-oncology candidates, including LOQTORZI, towards key data milestones in 2026, focusing on maximizing revenues and expanding indications.
clinical readout